Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome

Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome

RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY)

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME

Inclusion Criteria:

• Male or female between 6 and 30 years old.
• Clinical diagnosis of Angelman Syndrome and molecular confirmation of diagnosis.
• The participant has an acceptable guardian can give consent on behalf of the participant.

Exclusion Criteria:

• Patients with hypersensitivity to tetracyclines.
• Patients with impaired hepatic or renal function and in those with mainly drug allergy history.
• Any other condition that in the opinion of the investigator is considered clinically relevant and that administration of minocycline contraindicated